Research
Hormonal
A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group compared to 22.4% in the placebo group.
Semaglutide may help reduce liver fibrosis in patients with MASH.
StrongSupportsmedium confidence
A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group.
Why this rating
Based on the large randomized controlled trial design.
Source
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Arun J. Sanyal et al. · New England Journal of Medicine · 2025
rct · n=1197Cited 618×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →